Generate Biomedicines, Inc.

Item 5. Other Information.

(a) None.

(b) None.

(c) During the fiscal quarter ended March 31, 2026, the following director and executive officer adopted a trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act:

•

On March 13, 2026, Francis Arnold, a member of our board of directors, adopteda written trading plan (the “Arnold Plan”) for the sale of up to 232,472 shares of our common stock. The Arnold Plan is intended to satisfy the conditions of Rule 10b5-1(c) and was adopted during an open trading window and at a time when Ms. Arnold was not aware of material nonpublic information. The Arnold Plan provides for sales to commence on or after September 30, 2026 and to terminate on March 31, 2027, subject to earlier completion or termination in accordance with its terms.

•

On March 13, 2026, Sean Martin, Chief Legal Officer and General Counsel, adopteda written trading plan (the “Martin Plan” and together with the Arnold Plan, the "Plans") for the sale of up to 116,800 shares of the Company’s common stock. The Martin Plan is intended to satisfy the conditions of Rule 10b5-1(c) and was adopted during an open trading window and at a time when Mr. Martin was not aware of material nonpublic information. The Martin Plan provides for sales to commence on or after November 2, 2026 and to terminate on March 5, 2027, subject to earlier completion or termination in accordance with its terms.

Except as described above, none of our other directors or executive officers adopted or terminated a 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement (as defined in Item 408(c) of Regulation S-K) during the fiscal quarter covered by this report.